D. Errante

The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer

Giuseppe Toffoli, Erika Cecchin, Giuseppe Corona et al. · Journal of Clinical Oncology · 2006 · 337 citations · Full text

Medicine, Oncology, Pharmacology +17

Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors.

Umberto Tirelli, D. Errante, Riccardo Dolcetti et al. · Journal of Clinical Oncology · 1995 · 229 citations

Life Sciences, Infectious Diseases, Pathology +11

CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group.

Umberto Tirelli, D. Errante, M. van Glabbeke et al. · Journal of Clinical Oncology · 1998 · 219 citations

Medicine, Geriatric Medicine, Oncology +15

A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma.

Umberto Tirelli, Vittorina Zagonel, D. Errante et al. · Journal of Clinical Oncology · 1992 · 92 citations

Medicine, Oncology, Pharmacology +15

A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen

Erika Cecchin, Mario D’Andrea, Sara Lonardi et al. · The Pharmacogenomics Journal · 2012 · 76 citations

Medicine, Oncology, Pharmacology +16